Register for the ASCO post-show roundtable: Expert takeaways from the world's biggest cancer meeting
Join us on June 1st at 3:00pm ET / 12:00pm PT. Register today.
Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.
Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.
Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.